Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Fund eyes new investment stream in Deutsche Bank fund

This article was originally published in Clinica

Executive Summary

Deutsche Bank and the Global Fund to Fight AIDS, Tuberculosis and Malaria have signed a letter of intent to set up an exchange traded fund (ETF) to be listed and distributed in Europe and Asia. The ETF will track a global blue-chip index, developed by and licensed from Dow Jones Indexes and the Global Fund. The latter will receive a portion of the license and management revenues generated by the ETF – further details are to be announced in the last quarter of 2010. The agreement was signed today in London, by Robert Filipp, head of innovative finance at the Global Fund, and Thorsten Michalik, head of Deutsche Bank’s db x-trackers, a leading ETF with around €30bn ($38bn) in managed assets.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT095500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel